RxDoctor Payments Data

David Butzel, MD

Interventional Cardiology · Scarborough, MENPI 1801832589

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,443 of the $2,318 with a category attached, or 62.2%. 3 manufacturers reported payments, led by Abbott at 46.7% of the total. Reporting peaked in 2024 at $1,116 and has fallen 64.0% since, to $401 in 2025. That places this record below the midpoint for interventional cardiology clinicians in ME, where the typical reported total is $2,318.

$2,318in general payments, 2019–2025

Across 43 payments — averaging $53.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$1K
  • Edwards Lifesciences$1K
  • Medtronic$178
$71,789in research payments, 2019–2025

Across 24 payments — averaging $2991.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Edwards Lifesciences$49K
  • Medtronic$12K
  • Daiichi Sankyo Inc.$11K

What the payments were for

  • Travel & lodging$87638%
  • Food & beverage$1,44362%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Abbott8$1,083
Edwards Lifesciences34$1,058
Medtronic1$178

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,318 in reported general payments places this provider in the 50th percentile of 21 interventional cardiology providers in Maine.

See all interventional cardiology providers in Maine

Medicare billing

Part B allowed, 2024
$91,936
Medicare patients
552
Services billed
827

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ClopidogrelClopidogrel Bisulfate14$119

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Scarborough

See the full list for Maine

Where these figures come from

Is this you, or does something look wrong? →